Email Updates

You are here

Home

CONRAD A15-140

Status
Completed
Phase
I
Objective

This single site study is designed to describe and measure the efficacy of oral versus vaginal dosing of TFV-based products, specifically emtricitabine/tenofovir disoproxil fumarate oral tablets (Truvada) vs tenofovir intravaginal rings (IVR).

Prevention Option(s)
Microbicides
PrEP
Study Design
Open label
Arms and Assigned Interventions
Description
The participant will wear the intravaginal ring consecutively for 14 days and nights.
Mode of Delivery
Ring
Products
TFV ring
ARMs
Experimental
Description
The participant will take the tablet for 14 days.
Mode of Delivery
Tablet
Products
TDF/FTC (Truvada)
Official Code
NCT02722343
April 2016
August 2016
Enrollment
25
18
Years
50
Years
Population
Women
Sites

Eastern Virginia Medical School

Norfolk, Virginia
United States of America